Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03371485 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Cancer Research UKOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | completed | Phase 1 / Phase 2 | 220 | Astex Pharmaceuticals, Inc.INDUSTRY | 5 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT06521034 | First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer(Helpful) | completed | Phase 1 / Phase 2 | 124 | Yongchang ZhangOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03819387 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | completed | Phase 1 | 49 | Nitto BioPharma, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT03681483 | RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT00254384 | Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | completed | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06378658 | A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants | completed | Phase 1 | 21 | BayerINDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06360211 | A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants | completed | Phase 1 | 15 | BayerINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT01513174 | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone(GOAL) | completed | Phase 1 / Phase 2 | 186 | Spanish Lung Cancer GroupOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06221475 | A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | completed | Phase 1 | 8 | BayerINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06294561 | TGRX-326 Pharmacokinetic Drug Interaction | completed | Phase 1 | 34 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03847519 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 24 | Advaxis, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | completed | Phase 1 / Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02225405 | Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04967079 | Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | completed | Phase 1 | 33 | Shanghai Chest HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02581787 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 28 | Maximilian DiehnOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03535363 | Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | completed | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03607188 | Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer(NSCLC) | completed | Phase 1 | 17 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02922777 | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | completed | Phase 1 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02789345 | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03446417 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | completed | Phase 1 | 34 | Zeno Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 25, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02163733 | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 38 | AstraZenecaINDUSTRY | 4 | Jan 22, 2024 | clinicaltrials |
| NCT06209229 | Role of Neutrophils and Electro-bioluminescence in the Rehabilitation(RNE) | completed | Phase 1 | 34 | MIPO ClinicOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04299048 | Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | completed | Phase 1 | 11 | PfizerINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05159518 | A Study of PRT2527 in Participants With Advanced Solid Tumors | completed | Phase 1 | 30 | Prelude TherapeuticsINDUSTRY | 1 | Dec 11, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2024source: clinicaltrials